Immunogenicity in Clinical Practice and Drug Development: When is it Significant?

the

[1]  Maciej J. Swat,et al.  A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins , 2019, CPT: pharmacometrics & systems pharmacology.

[2]  Craig J. Thalhauser,et al.  Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1 , 2019, The AAPS Journal.

[3]  S. Snapper,et al.  The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease. , 2018, Inflammatory bowel diseases.

[4]  P. Klimiuk,et al.  Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study , 2018, Annals of the rheumatic diseases.

[5]  S. Vermeire,et al.  Immunogenicity of biologics in inflammatory bowel disease , 2018, Therapeutic advances in gastroenterology.

[6]  M. Weinblatt,et al.  Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis , 2017, Arthritis & rheumatology.

[7]  Stanley B. Cohen,et al.  Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study , 2017, Annals of the rheumatic diseases.

[8]  N. Vande Casteele.  Assays for measurement of TNF antagonists in practice , 2016, Frontline Gastroenterology.

[9]  P Vicini,et al.  A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 2—Model Applications , 2014, CPT: pharmacometrics & systems pharmacology.

[10]  M. Jamei,et al.  Simulation of Monoclonal Antibody Pharmacokinetics in HumansUsing a Minimal Physiologically Based Model , 2014, The AAPS Journal.